Home Cart Sign in  
Chemical Structure| 19879-30-2 Chemical Structure| 19879-30-2

Structure of Bavachinin
CAS No.: 19879-30-2

Chemical Structure| 19879-30-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bavachinin is an agonist of PPAR with EC50s of 4.0 µM, 8.1 µM, and 0.74 µM for α,β/δ, and γ respectively. It is a natural flavanone with anti-angiogenic effect.

Synonyms: 7-O-Methylbavachin; Bavachinin A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bavachinin

CAS No. :19879-30-2
Formula : C21H22O4
M.W : 338.40
SMILES Code : O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=C1C=C(C/C=C(C)\C)C(OC)=C3
Synonyms :
7-O-Methylbavachin; Bavachinin A
MDL No. :MFCD06858307
InChI Key :VOCGSQHKPZSIKB-FQEVSTJZSA-N
Pubchem ID :10337211

Safety of Bavachinin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 0.1-0.2 μM 24-72 h Evaluate the effect of Bavachinin on HepG2 cell proliferation, results show low concentrations of Bavachinin promote cell proliferation. J Adv Res. 2024 Jan;55:131-144
16HBE 0, 10, 20, 30 μM 24, 48, 72 h To evaluate the cytotoxic effect of Bavachinin on normal lung epithelial cell viability, results showed repression of cell viability only after 30 μM Bavachinin treatment for 48 and 72 hours. Molecules. 2021 Aug 25;26(17):5161
HCC827 0, 10, 20, 30 μM 24, 48, 72 h To evaluate the cytotoxic effect of Bavachinin on NSCLC cell viability, results showed a dose- and time-dependent decrease in cell viability. Molecules. 2021 Aug 25;26(17):5161
splenocytes 10 nM 48 h Bavachinin significantly reduced the percentage of GFP-positive cells and inhibited the mRNA expression of IL-4, IL-5, and IL-13 Cell Mol Immunol. 2013 Nov;10(6):497-505

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Golden hamsters High fat diet-induced NAFLD model Oral 50 and 100 mg/kg Once daily for 4 weeks Evaluate the liver-protective and lipid-lowering effects of Bavachinin in NAFLD hamsters, results show Bavachinin improves liver histology and reduces lipid levels. J Adv Res. 2024 Jan;55:131-144
Mice OVA-sensitized asthma model Oral gavage 50 mg/kg Once daily for 7 days Bavachinin significantly reduced the thickness of the bronchial wall and the area of airway smooth muscle, decreased airway hyperreactivity, and inhibited serum levels of IL-4 and IgE Cell Mol Immunol. 2013 Nov;10(6):497-505

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.78mL

2.96mL

1.48mL

29.55mL

5.91mL

2.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories